[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infection-viral\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infection-viral":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,90,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100601449","microbial-cell-free-metagenomic-sequencing-for-suspected-infections-in-adult-immunocompromised-outpatients-100601449",false,"NCT07110636","Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients","A Prospective Randomized Basket Trial Evaluating the Clinical Utility of Plasma-based Microbial Cell-free Metagenomic Sequencing for Diagnosis and Management of Suspected Infections in Adult Immunocompromised Outpatients","OPTIMUM","Inclusion Criteria:\n\n* Basket Protocol\\* All participants must meet inclusion\n\n  1. Age ≥18\n  2. Included in one of the following immunocompromised groups: Solid organ transplant recipient (SOT) on chronic immunosuppression; Diagnosed with hematologic malignancy (HM) and\u002For recipient of a hematopoietic cell transplant (HCT); Diagnosed with a solid tumor and on specific types of active treatment; Recipient of drugs or novel biologics causing chronic immunosuppression; Diagnosed with an HIV infection; Diagnosed with inborn errors of immunity\n  3. Treating provider suspects infection and plans to obtain usual care diagnostic testing for the suspected infection (i.e., microbiologic testing)\n  4. Willing to provide research samples via blood draw\n  5. Willing and able to provide informed consent\n  6. Presenting for evaluation in the outpatient setting (includes telehealth)\n\n     \\*For Participants enrolled in Sub-Protocol A- Solid Organ Transplant\\*\n\n     All Sub-Protocol A subjects must meet the following:\n\n  \u003C!-- -->\n\n  1. Solid organ transplant recipient on transplant immunosuppression Non-lung recipients must meet one or more of the following characteristics: \\\u003C1 year from transplant; Augmented immunosuppression for suspected or confirmed rejection within the last 6 months; Confirmed systemic infection in last 6 months\n  2. Suspected infection defined by one or more of the syndromes: Cardiac; Lower Respiratory; Gastrointestinal \u002F Hepatobiliary; Genitourinary; Neurologic \u002F Ophthalmologic; Skin \u002F Soft tissue \u002F musculoskeletal; Not Otherwise Specified\n* For Participants enrolled in Sub-Protocol B- Hematological Malignancies and Transplant\\* All Sub-Protocol B subjects must meet the following:\n\n  1. Is included in at least one of the following groups: Hematologic malignancy (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma) and at least one of the following: Received chemotherapy or other systemic anti-cancer therapy associated with immunosuppressive effects within 90 days (e.g., monoclonal antibodies associated with B-cell or plasma cell depletion, bi-specific t-cell engagers, BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors) within the last 90 days Note: Checkpoint inhibitors are not included unless given in combination with an immunosuppressive agent; Relapsed disease with chemotherapy anticipated in 60 days; ANC \\\u003C500 within the last 72 hours; Hypogammaglobulinemia IgG \\\u003C400 within the last 30 days; Allogeneic stem cell transplant for any clinical indication and at least one of the following: Within 1-year post-transplant; On systemic immunosuppressive therapy for GVHD treatment or prophylaxis; Autologous stem cell transplant for hematologic malignancy and at least one of the following: Within 6 months post-transplant; ANC \\\u003C500 within the last 72 hours; B cell and plasma cell targeted CAR-T therapy for hematologic malignancy and at least one of the following: Within 6 months of CAR-T cell infusion; CD4 T-cell \\\u003C200 within the last 30 days; IgG \\\u003C 400 within the last 30 days; ANC \\\u003C500 within the last 72 hours; On systemic immunosuppressive therapy for CRS\u002FICANS\n  2. Suspected infection defined by one or more of the syndromes: Cardiac; Lower Respiratory; Gastrointestinal \u002F Hepatobiliary; Genitourinary; Neurologic \u002F Ophthalmologic; Skin \u002F Soft tissue \u002F musculoskeletal; Not Otherwise Specified\n\nExclusion Criteria:\n\n* Basket Protocol\\* All participants must not meet the following:\n\n  1. Active symptoms are likely attributed to non-infectious causes.\n  2. Any other clinically significant medical condition that, in the opinion of the treating provider, makes participation undesirable, including but not limited to severe psychiatric illness, etc.\n\n     \\*For Participants enrolled in Sub-Protocol A- Solid Organ Transplant\\*\n\n     All Sub-Protocol A subjects must not meet the following:\n\n  \u003C!-- -->\n\n  1. Patients who have been previously evaluated (including via telehealth) for the same clinical signs and symptoms at this institution and pathogen-directed usual care (UC), diagnostic testing was ordered during that prior encounter, with one or more diagnostic test results still pending.\n  2. Patients with a suspected or confirmed primary upper respiratory infection (e.g., viral pharyngitis, sinusitis, or uncomplicated bronchitis) unless there is clinical suspicion of a concurrent lower respiratory or systemic infection requiring further diagnostic evaluation.\n* For Participants enrolled in Sub-Protocol B- Hematological Malignancies and Transplant\\* All Sub-Protocol B subjects must not meet the following:\n\n  1. Patients that have been previously evaluated (including via telehealth) for the same clinical signs and symptoms at this institution and pathogen-directed usual care (UC) diagnostic testing was ordered during that prior encounter with one or more diagnostic tests results still pending.\n  2. Patients with a suspected or confirmed primary upper respiratory infection (e.g., viral pharyngitis, sinusitis, or uncomplicated bronchitis) unless there is clinical suspicion of a concurrent lower respiratory or systemic infection requiring further diagnostic evaluation.","ALL","18 Years",{"count":20,"type":21},2000,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection in the outpatient setting leads to faster infection diagnosis and treatment. Participants will give a blood sample one time to be used for the testing. Information about the participant's illness and any treatments within 30 days following enrollment will be recorded.",[27,28,29,30,31],"Infection","Infections, Bacterial","Infections, Fungal","Infection Viral","Parasitic Disease",[33,34,35,36,37,38,39,40,41],"Karius","Karius Spectrum","Infection detection","metagenomic testing","Pathogen detection","Bacterial Infection","Fungal Infection","Parasitic Infection","Viral Infection","RECRUITING","2026-01-28",{"date":45,"type":46},"2026-01-30","ACTUAL",{"date":48,"type":46},"2025-10-27",{"date":50,"type":21},"2028-12-31",{"name":52,"class":53},"Karius, Inc.","INDUSTRY",6,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":74,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100529826","towards-novel-biomarkers-to-diagnose-sepsis-on-the-emergency-room-100529826","NCT06178822","Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room","BIOSEP","Inclusion Criteria:\n\n* Age 18 years or higher\n* Presentation at the Emergency Department (ED)\n* Clinical suspicion of infection or earlier confirmed infection\n* Modified Early Warning Score (MEWS) of 2 or higher\n\nExclusion Criteria:\n\n* No informed consent given",{"count":63,"type":21},3300,"1 Year","OBSERVATIONAL","Objectives:\n\n1. To compare the immune response of patients with or without sepsis presenting to the ED with a(n) (suspected) infection.\n2. To determine immune response aberrations that are associated with an increased risk of developing sepsis in patients presenting to the ED with a(n) (suspected) infection without sepsis.\n3. To determine the long term cognitive and physical sequelae of sepsis after admission.",[68,69,70,71,30,72,73],"Sepsis","Septic Shock","Sepsis, Severe","Infections","Infection, Bacterial","Infections, Respiratory",[75,76,77,78],"Biomarkers","Emergency Room","A&E","Accident & Emergency","2025-09-29",{"date":81,"type":46},"2025-10-02",{"date":83,"type":46},"2022-10-25",{"date":85,"type":21},"2026-10-01",{"name":87,"class":88},"Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)","OTHER",3,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":97,"sex":17,"minAge":18,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100538117","xanthohumol-and-viral-infections-xl-100538117","NCT06286657","Xanthohumol and Viral Infections (XL)","Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans","Inclusion Criteria:\n\n* healthy\n* BMI \\>18 kg\u002Fm² or \\\u003C 28kg\u002Fm²\n\nExclusion Criteria:\n\n* food intolerances\n* food allergies\n* chronic inflammatory diseases\n* metabolic diseases\n* viral or bacterial infections within the last 3 weeks of inclusion\n* intake of immunosuppressive medication\n* severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months\n* influenza infection in the \"current\" flu season",true,"70 Years",{"count":100,"type":21},100,[24],"The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.",[30],"2025-04-10",{"date":106,"type":46},"2025-04-15",{"date":108,"type":46},"2023-08-01",{"date":110,"type":21},"2025-12-30",{"name":112,"class":88},"University of Vienna",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":127,"conditions":128,"keywords":133,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":113},"100348556","phase-2-post-transplant-cyclophosphamide-in-matched-unrelated-donor-stem-cell-transplantation-for-hematological-malignancies-100348556","NCT03818334","Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies","Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Men and Women of Any Age\n* Indication for an HSCT without matched sibling donor\n* Have a matched unrelated donor (HLA 10 x 10 or 9 x 10)\n* Hematological malignancy\n\nExclusion Criteria:\n\n* Acute leukemias not in complete response (that is \\> 5% blast in the bone marrow)\n* Chemorefractory lymphoproliferative disease\n* Active uncontrolled infection\n* HCT-CI \\> 3\n* Severe organic disfunction (heart ejection fraction \\\u003C 45%, glomerular filtration rate \\\u003C 50 mL.hour, pulmonary DLCO \\\u003C 50%)\n* Previous allogeneic bone marrow transplantation\n* Contraindication to cyclophosphamide or ATG","75 Years",{"count":123,"type":21},50,[125,126],"PHASE2","PHASE3","This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).",[129,130,30,131,132],"Bone Marrow Transplant Complications","Graft Versus Host Disease","Engraft Failure","Immunologic Suppression",[134,135,136],"Bone Marrow Transplantation","Hematological Malignancies","Post-Cy","2019-01-31",{"date":139,"type":46},"2019-02-01",{"date":141,"type":46},"2018-11-06",{"date":143,"type":21},"2026-11-01",{"name":145,"class":88},"Hospital Israelita Albert Einstein"]